Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta‑analysis

  • Authors:
    • Jing Yang
    • Jingjing Li
    • Weiqi Dai
    • Fan Wang
    • Miao Shen
    • Kan Chen
    • Ping Cheng
    • Yan Zhang
    • Chengfen Wang
    • Rong Zhu
    • Huawei Zhang
    • Yuanyuan Zheng
    • Junshan Wang
    • Yujing Xia
    • Jie Lu
    • Yingqun Zhou
    • Chuanyong Guo
  • View Affiliations

  • Published online on: January 29, 2015     https://doi.org/10.3892/etm.2015.2231
  • Pages: 1413-1420
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and the third leading cause of cancer‑related mortality worldwide. Conflicting results have been reported regarding the use of serum Golgi protein 73 (GP73) as a promising serum marker for the diagnosis of HCC; therefore, the aim of the present study was to provide a systematic review of the diagnostic performance of GP73 for HCC. Following a systematic review of the relevant studies, a number of indices associated with the accuracy of the diagnostic performance of GP73, including the sensitivity and specificity, were pooled using Meta Disc 1.4 software. Data were presented as forest plots, and summary receiver operating characteristic (SROC) curve analysis was used to summarize the overall test performance. Eleven studies were included in this meta‑analysis. The summary estimates for serum GP73 in diagnosing HCC were as follows: Sensitivity, 77% [95% confidence interval (CI), 75‑79%]; specificity, 91% (95% CI, 90‑92%); positive likelihood ratio, 4.34 (95% CI, 2.19‑8.59); negative likelihood ratio, 0.30 (95% CI, 0.26‑0.36) and diagnostic odds ratio, 15.78 (95% CI, 6.95‑35.83). The area under the SROC curve was 0.8638, and the Q index was 0.7944. Significant heterogeneity was found. This meta‑analysis indicates a moderate diagnostic value of GP73 in HCC; however, further studies with rigorous design, large sample size and multiregional cooperation are required.
View Figures
View References

Related Articles

Journal Cover

April-2015
Volume 9 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang J, Li J, Dai W, Wang F, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Zhu R, Zhu R, et al: Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta‑analysis. Exp Ther Med 9: 1413-1420, 2015.
APA
Yang, J., Li, J., Dai, W., Wang, F., Shen, M., Chen, K. ... Guo, C. (2015). Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta‑analysis. Experimental and Therapeutic Medicine, 9, 1413-1420. https://doi.org/10.3892/etm.2015.2231
MLA
Yang, J., Li, J., Dai, W., Wang, F., Shen, M., Chen, K., Cheng, P., Zhang, Y., Wang, C., Zhu, R., Zhang, H., Zheng, Y., Wang, J., Xia, Y., Lu, J., Zhou, Y., Guo, C."Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta‑analysis". Experimental and Therapeutic Medicine 9.4 (2015): 1413-1420.
Chicago
Yang, J., Li, J., Dai, W., Wang, F., Shen, M., Chen, K., Cheng, P., Zhang, Y., Wang, C., Zhu, R., Zhang, H., Zheng, Y., Wang, J., Xia, Y., Lu, J., Zhou, Y., Guo, C."Golgi protein 73 as a biomarker for hepatocellular carcinoma: A diagnostic meta‑analysis". Experimental and Therapeutic Medicine 9, no. 4 (2015): 1413-1420. https://doi.org/10.3892/etm.2015.2231